Skip to main content

Levy Richard S's Form 4 filing

Madrigal Pharmaceuticals, Inc. (MDGL) · filed Jan 19, 2023

Accession no.
0000899243-23-002219
Filed
Jan 19, 2023
Trade date
Jan 17, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 12 non-derivative transactions and 2 derivative transactions. Open-market sales total $6.59M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Levy Richard SCIK 0001454983Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 17, 2023Common StockMOption exerciseAcquired+12,489$105.08+$1,312,344.1221,589Direct
Jan 17, 2023Common StockMOption exerciseAcquired+10,000$100.45+$1,004,50031,589Direct
Jan 17, 2023Common StockSSaleDisposed−100$285.28−$28,52831,489Direct
Jan 17, 2023Common StockSSaleDisposed−400$287.08F4−$114,83231,089Direct
Jan 17, 2023Common StockSSaleDisposed−300$288.91F5−$86,67330,789Direct
Jan 17, 2023Common StockSSaleDisposed−1,600$290.36F6−$464,57629,189Direct
Jan 17, 2023Common StockSSaleDisposed−3,325$291.66F7−$969,769.525,864Direct
Jan 17, 2023Common StockSSaleDisposed−5,227$292.68F8−$1,529,838.3620,637Direct
Jan 17, 2023Common StockSSaleDisposed−3,548$293.54F9−$1,041,479.9217,089Direct
Jan 17, 2023Common StockSSaleDisposed−5,164$294.68F10−$1,521,727.5211,925Direct
Jan 17, 2023Common StockSSaleDisposed−2,325$295.45F11−$686,921.259,600Direct
Jan 17, 2023Common StockSSaleDisposed−500$296.68F12−$148,3409,100Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 17, 2023Common StockMOption exerciseDisposed−12,489$0.00$00Direct
Jan 17, 2023Common StockMOption exerciseDisposed−10,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $286.99 to $287.16, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $288.73 to $289.01, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $289.80 to $290.79, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $291.08 to $292.07, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $292.11 to $293.09, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.12 to $294.11, inclusive.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $294.17 to $295.16, inclusive.

Referenced by the price of 1 transaction in Table I.

F11

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $295.26 to $296.15, inclusive.

Referenced by the price of 1 transaction in Table I.

F12

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $296.43 to $296.77, inclusive.

Referenced by the price of 1 transaction in Table I.

Remarks

** As attorney-in-fact for Reporting Person

Read the full filing on SEC EDGAR (opens in a new tab)